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Abstract
Background: Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made
in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is
a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB,
which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is
crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program
in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment
outcomes under DOTS-Plus.
Methods: A systematic review and meta-analysis of published literature was conducted. Original studies were identified
using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using
the Cochran’s Q test and I2 statistic. Pooled estimates of treatment outcomes were computed using the random effect
model.
Results: Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients
reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4–68.5%) successfully completed full
treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0–16.2%) of the
patients died, 14.2% (95% CI: 11.6–16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6–9.7%) failed therapy. Overall 35.
4% (95% CI: 30–40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43%
(95% CI: 32–54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized
treatment regimens.
Conclusion: This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared
to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this
literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success
rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further
individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and
multi-center studies.
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Background
Anti-tuberculosis (TB) drug resistance is a major public
health problem, which threatens the progress made in
the control of TB worldwide. Drug resistance occurs due
to the improper use of antibiotics during chemotherapy
of drug-susceptible TB patients. This incorrect use is a
result of a number of factors such as administration of
inappropriate treatment regimens and failure to ensure
that patients complete the whole course of treatment [1].
Globally, 5% of TB cases were estimated to have devel-
oped multidrug-resistant TB (MDR-TB) (defined as resist-
ance to at least isoniazid and rifampin) in 2013 (3.5% new
and 20.5% previously treated TB cases). Likewise, drug
resistance surveillance data have shown that an esti-
mated 480 000 people developed MDR-TB worldwide
in 2013, and out of this, 210 000 people died [1]. In
1999, the Green Light Committee (GLC), a partner of
the World Health Organization (WHO), launched the
“directly observed treatment, short-course (DOTS)-Plus
for MDR-TB” programs for patients with MDR-TB. The
program emphasizes the usage of appropriate second-line
drugs (SLDs) in low- and middle-income settings. By the
end of 2006, more than 50 DOTS-Plus pilot programs
had been launched by GLC, and more than 20 000
patients with MDR-TB were under treatment [2].
The DOTS-Plus program, which stresses the combin-
ation of first- and second-line drugs to treat MDR-TB, is
becoming increasingly important for MDR-TB control
globally. The core components are comprehensive to
ensure that all essential elements of the DOTS-Plus strat-
egy are included. They are the following: sustained political
and administrative commitment; diagnosis of MDR-TB
through quality-assured culture and drug susceptibility
testing; appropriate treatment strategies that utilize SLDs
under proper management conditions; and uninterrupted
supply of quality-assured anti-TB drugs [3].
Treatment of MDR-TB involves the use of SLDs, which
are more complex, toxic, costly, and less effective, are asso-
ciated with a greater incidence of adverse reactions [4, 5],
and require longer treatment duration than first-line drugs.
The WHO aimed to achieve the target of at least 75 to
90% treatment success rate for TB patients by 2015 [6],
but current studies on MDR-TB treatment reveal a huge
gap in reaching this target. According to a WHO 2014
report, only 48% of patients with MDR-TB in 2011 were
successfully treated, 16% died, 24% did not have their
treatment outcomes documented or interrupted treat-
ment, and 12% were not cured despite receiving treat-
ment [1]. Hence, unsuccessful treatment of MDR-TB is
a key problem that cannot be neglected. There is a paucity
of evidence that assessed studies on the treatment of MDR-
TB, which focus on the effectiveness of the directly ob-
served treatment, short-course (DOTS)-Plus program [7].
Therefore, it is very important to review and summarize
the overall treatment outcomes for MDR-TB under DOTS-
Plus in recent years. The aim of this study was to assess
and summarize the available evidence on MDR-TB treat-
ment outcomes under DOTS-Plus.
Methods
Study design and data sources
A systematic review and meta-analysis of published
observational studies was conducted. Original studies
providing information on the treatment outcomes of
patients with MDR-TB under DOTS-Plus were identified
through a computerized search using the databases
MEDLINE®/PubMed®, Google Scholar, Embase®, and Health
InterNetwork Access to Research Initiative (Hinari). A
detailed search strategy was implemented and reference
lists were cross-checked. A combination of keywords
and phrases, namely “tuberculosis”, “drug resistance”,
“multidrug resistance”, “DOTS-Plus”, “MDR-TB”, and
“treatment outcomes” were used to search for articles
in the databases. The International Journal of Tuberculosis
and Lung Disease was selected as the key journal for hand
searching. At the same time, a hand search was also done
for cross-reference lists from identified original articles
and reviews for other relevant articles. The literature
search, review, and data abstraction was performed from
February 1 to August 30, 2015.
Study selection
Observational studies obtained from the literature search
were checked by title and citation. References from the
selected studies were also assessed to ensure that no
relevant studies were omitted. Studies were required to
meet the following inclusion criteria: 1) involving culture-
confirmed MDR-TB; 2) treatment outcome definitions
specified by mycobacterial culture endpoints (e.g., “cured”
defined as at least five consecutive negative cultures dur-
ing the last 12 months of treatment); 3) clearly defined
treatment protocols including SLDs; and 4) outcomes
reported according to the WHO classification of success
(including cure or treatment completion), failure, default
(treatment interruption), and death [8]. Reports on ori-
ginal studies, unpublished master’s theses, and PhD dis-
sertations written in English were also considered.
Studies were excluded from the analysis for any of the
following reasons: involving patients who all had exten-
sively drug-resistant TB; comments, editorial reviews, and
articles focusing only on extrapulmonary TB; dealing with a
mycobacterium other than TB; conducted among children
under 15 years of age; focusing on treatment that was not
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under the DOTS-Plus umbrella; did not specify strategy;
duplicate publications of the same study; available only in
abstract form; and with a sample size of less than 10. The
selection of articles for review was done in three stages:
looking at the titles alone, then abstracts, and then full-text
articles (see Fig. 1).
Operationalization of outcome measures
Treatment outcomes of MDR-TB were defined based on
the WHO guidelines, as follows [1]:
 Cured: defined as a patient who had completed
treatment according to program protocol and who
has been consistently culture-negative (with at
least five results) for the final 12 months of
treatment.
 Treatment completed: defined as a patient who had
completed treatment according to program
protocols, but does not meet the definition of
“cured” because of a lack of bacteriological results.
 Died: defined as a patient who died for any reason
during the course of TB treatment.
 Treatment failed: if two or more of the five
cultures recorded in the final 12 months of
treatment were positive, or if any one of the final
three cultures was positive.
 Lost to follow-up: defined as a patient whose TB
treatment was interrupted for two or more
consecutive months for any reason.
 Transferred out: defined as a patient who had been
transferred to another reporting and recording unit,
and for whom the treatment outcome was
unknown.
For the purposes of this review, those cured or who
completed their treatment was categorized as successful
treatment outcomes, whereas the others were catego-
rized as unsuccessful treatment outcomes.
Assessment of methodological quality
Studies were assessed for quality and the high-quality
studies were then analyzed. The studies were considered
high quality if they reported outcomes on at least 10
patients; involved culture-confirmed MDR-TB; were
prospective cohort (PC), retrospective cohort (RC), or
case control in design; reported an average treatment
duration of ≥18 months; reported basic demographic
data; and reported that less than 20% of patients were
lost to follow-up. When study populations overlapped,
we included the more recent and larger study popula-
tion in the analysis.
Data abstraction
Two reviewers (YM and KTK) performed data abstraction
independently using a pretested standard abstraction form.
The selected studies were reviewed to extract the following
data: title; author(s); year of publication; study design; study
site; sample size; data collection procedures; type of
Fig. 1 Flow chart showing the selection of studies for systematic review (identification and screening, eligible and included studies). NB: Articles
may have been excluded for more than one reason
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MDR-TB (primary, acquired); HIV status; duration of
MDR-TB treatment; MDR-TB regimen (individualized
treatment versus standardized treatment); response
rates; and MDR-TB treatment outcomes. When there
was a disagreement in data abstraction between the
two investigators, it was resolved through discussion
and consensus.
Statistical analysis
Epi Data version 3.1 (EpiData Data Entry, Data Man-
agement and basic Statistical Analysis System. Odense
Denmark, EpiData Association) and Stata version 11.0
(Stata Corp., College Station, Texas, USA) were used
for data entry and analysis, respectively. The detail
description of the original studies was presented in a
table and forest plot. The pooled estimate of MDR-TB
treatment was determined using the Dersimonian-
Laird for random effects meta-analysis (random effects
model), and was measured as proportions of treatment
outcomes with 95% confidence intervals (CIs).
Subgroup analysis
Subgroup analyses was performed by type of treatment
regimen.
Statistical heterogeneity and exploration of publication bias
The Begg’s rank correlation test and Egger weighted re-
gression test were used to statistically assess publication
bias, and p < 0.05 was considered as indicative of statisti-
cally significant publication bias.
Statistical heterogeneity between studies was evaluated
using the Cochran’s Q test, which shows the amount
between study heterogeneity and I2 statistic. The I2 statistic
is a measure of the percentage of variability (inconsistency)
between studies that happened due to by chance as con-
flicted to the actual difference between study populations.
Therefore, the presence of statistical heterogeneity was
tested using Cochran’s Q test (P < 0.10 indicative of sta-
tistically significant heterogeneity) and I2 test (values of
25, 50 and 75% were considered to represent low, medium,
and high heterogeneity, respectively) [9–11].
Results
We identified a total of 203 original articles, from the
initial computer-based search, in the databases PubMed®,
Hinari, and Google Scholar. Nine additional articles were
identified through hand searching. Of these, 149 studies
were excluded: 71 were duplicated studies, 19 did not
examine patients with MDR-TB, 24 were not targeting
MDR-TB treatment outcomes, and 35 did not describe
treatment under DOTS-Plus. Therefore, 63 full-text studies
were eligible for in-depth analysis. Here again, after a care-
ful evaluation, two were excluded because of language
restrictions (not English), 42 were excluded because they
failed to report on standard outcomes, and five were ex-
cluded as they involved sample sizes of less than 10 patients
with MDR-TB. Finally, the 14 remaining articles were used
for the meta-analysis, including a total study population of
5047 patients from eight high-burden MDR-TB countries,
namely Peru, Latvia, Estonia, Russia, the Philippines, India,
South Africa, and Uzbekistan (including Karakalpakstan).
Figure 1 shows how the studies were selected.
Characteristics of studies included in the review
All of the studies selected for systemic review and meta-
analysis were observational studies, 10 of which were RC
studies, while four of which were PC studies. All of the
studies were published in English, with study popula-
tions varying from 52 to 1 768, and undertaken between
1997 and 2013. General characteristics and description
of the studies selected for the meta-analysis are outlined
in Table 1.
Treatment outcomes
The lowest cure rate (21%) was reported in a study con-
ducted in South Africa and the highest cure rate (77%)
was reported in a study conducted in Russia.
The meta-analysis of the 14 studies, in which SLDs
under the DOTS-Plus program in individualized or stan-
dardized protocols were administered, determined that 5
047 patients reported treatment outcomes, with 63.5%
(58.4%, 68.5) meeting the definition of successful treat-
ment (cured or treatment completed). The pooled cure
rate was 55.6%, whereas 12.6% (9.0, 16.2) of the patients
died, 14.2% (11.6, 16.8) defaulted from therapy, and 7.6%
(5.6, 9.7) failed therapy (see Fig. 2). The overall percent-
age of unsuccessful treatment outcomes was 35.4% (30,
40.8) (see Fig. 3).
According to a subgroup analysis, in the eight studies
that reported on individualized treatment regimens for pa-
tients with MDR-TB, the pooled proportion of patients
achieving treatment success was 67.2% (63.7, 70.7) (see
Fig. 4), with a cure rate of 62.7% (57.2, 68.2). The pooled
proportion of patients who had unsuccessful treatment
outcomes was 30.85% (27.5, 34.2) (see Fig. 5), with treat-
ment failure, default, and death rates of 8.4, 13 and 8.4%,
respectively. On the other hand, in the five studies in
which MDR-TB patients were under standardized treat-
ment regimens, the pooled proportion of patients success-
fully treated was 56.9% (45.9, 67.9) (see Fig. 4), with a cure
rate of 50.9% (26.8, 75). The pooled proportion of patients
who had unsuccessful treatment outcomes was 43% (32,
54) (see Fig. 5), with failure, default (treatment interrup-
tion), and death rates of 6.9, 16.6 and 20.2%, respectively.
Discussion
To determine the pooled treatment success rate of patients
with MDR-TB enrolled in DOTS-Plus programs and thus
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receiving SLDs, we analyzed data from 14 studies in eight
countries, which reported on treatment outcomes for a
total of 5 047 patients. The results of this meta-analysis
revealed that high proportions of patients had poor treat-
ment outcomes. The subgroup analysis further showed that
treatment success rate was higher in studies that reported
on individualized treatment regimens.
Standardized treatment ensures that all patients with
MDR-TB receive the same treatment regimens involving
a common drug susceptibility test (DST) of the prevalent
MDR-TB strains. Individualized treatment, on the other
hand, highlights the provision of treatment based on a
previous history of anti-TB treatment, while also taking
into account DST results from the most recent isolate
obtained from the patient [12, 13].
Empirically, an individualized treatment strategy for
MDR-TB requires ready access to reliable laboratory
facilities and to healthcare providers who are trained to
prescribe the regimens and interpret the results [14]. It
is likely that individualized treatment may be very
Table 1 Summary of the 14 observational studies assessing the treatment outcomes for patients with MDR-TB under DOTS-Plus that
were included in the meta-analysis (n = 14)
Study authors Study location Study period Study design Sample size HIV (%) Treatment duration Treatment
regimen
Kurbatova et al. [16] Five countriesa 2000–2003 RC 1768 1.6 Individualized
Singla et al. [17] India 2002–2006 RC 126 – 24–27 months Standardized
Keshavjee et al. [18] Russia 2000–2004 RC 579 0.9 ≥24 months Individualized
Riekstina et al. [19] Latvia 2002 RC 75 – 24 months Individualized
Cox et al. [20] Karakalpakstan, Uzbekistan 2003–2005 PC 87 – ≥24 months Individualized
Shin et al. [21] Russia 2000–2002 RC 244 0 ≥12 months Individualized
Holtz et al. [22] Latvia 2000 RC 167 – 12–18 months after conversion Individualized
Leimane et al. [23] Latvia 2000 RC 204 0.5 12–18 months after conversion Individualized
Tupasi et al. [24] Philippines 1999–2002 PC 149 – ≥24 Months Individualized
Arora et al. [25] India 2002–2005 RC 52 – 24 months Standardized
Mitnick et al. [26] Peru 1999–2002 RC 651 1.5 15 months after conversion Standardized
Jain et al. [27] India 2009 PC 130 – 24 months Standardized
Farley et al. [28] South Africa 2000–2004 PC 757 38 12–18 months after conversion Standardized
Van Deun et al. [14] Bangladesh 1997–1999 RC 58 – 24 months Standardized
aThe five countries were Peru, Latvia, Estonia, Russia, and the Philippines
Fig. 2 Forest plot of the 14 observational studies that quantitatively assessed successful MDR-TB treatment outcomes under DOTS-Plus
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difficult to administer in resource-limited settings, as com-
pared to standardized treatment. However, individualized
treatment improves selection of effective drugs that can
result in high treatment success for patients and prevents
the acquirement of a further resistance strain.
Our study, unlike previous reviews [7, 15], solely focused
on MDR-TB treatment outcomes under the recently imple-
mented DOTS-Plus program. Previous systematic reviews
and meta-analyses of studies on MDR-TB included treat-
ment outcomes under all programs (including DOTS, and
DOTS-Plus). Our meta-analysis showed that the treatment
success rate was 63.48%. This finding is consistent with two
previous reviews. According to Orenstein et al. [7] and
Johnston et al. [15] meta-analysis studies, the overall pooled
prevalence of MDR-TB treatment success estimates
were 62% (95% CI, 58–67%) and 62% (95% CI, 57–
67%), respectively.
The WHO aimed to achieve at least 75 to 90% treat-
ment success rate for TB patients by 2015 [6], and to ad-
minister better treatment for MDR-TB patients. To do
Fig. 3 Forest plot of the 14 observational studies that quantitatively assessed unsuccessful MDR-TB treatment outcomes under DOTS-Plus
Fig. 4 Forest plot of the 13 observational studies that quantitatively assessed successful MDR-TB treatment outcomes under DOTS-Plus by
treatment regimen
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this, in 1992, the WHO launched the “DOTS-Plus for
MDR-TB” programs aimed at MDR-TB patients, stressing
the appropriate usage of SLDs in low- and middle-income
settings [2]. But the current pooled analysis showed that
there are huge gaps in achieving this target and that the
DOTS-Plus strategy does not result in significant changes
in MDR-TB treatment success rates, this implicates that
more stringent activities and mobilization of resources for
the treatment and control of MDR-TB is required than
ever made.
The current review and meta-analysis of 14 observa-
tional studies revealed high rates of default (14.2%) and
death (12.6%). Similar findings were reported in previous
systematic review studies: Johnston et al. [15] reported a
13% (9–17%) default rate and a 11% (9–13%) death rate,
and Orenstein et al. [7] found that the default and death
rates were 12% (8–16) and 11% (7–15), respectively.
Even though the treatment success rate was encour-
aging, the current review revealed that the DOTS-Plus
treatment strategy cannot achieve the WHO treatment
success target [6].
Limitations of the study
Our review had several limitations. We relied exclu-
sively on observational data for treatment outcomes.
This may underestimate pooled treatment outcomes.
Secondly, this study only searched for studies pub-
lished in English, which may have resulted in informa-
tion being missed about the DOTS-Plus program for
MDR-TB reported in other languages. Presence of high
heterogeneity across studies is another limitation of
this review.
Conclusion
This meta-analysis revealed that a low MDR-TB treat-
ment success rate among patients, which is far from
the WHO target to be achieved by 2015. A significant
proportion of patients defaulted from treatment (14%),
or died (12.6%), which is a serious public health concern
that needs to be addressed urgently. The high default rate
could possibly explain the spread of the MDR-TB strain in
various populations. Better treatment success rates were
observed among patients in individualized treatment regi-
mens rather than in standardized ones. Further individual-
based meta-analysis is recommended to identify potential
factors for defaulting treatment using large-scale and multi-
center studies.
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